Last reviewed · How we verify
RinGlar®
RinGlar is a glucagon-like peptide-1 (GLP-1) receptor agonist.
RinGlar is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.
At a glance
| Generic name | RinGlar® |
|---|---|
| Also known as | insulin glargine |
| Sponsor | Geropharm |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by mimicking the action of the natural hormone GLP-1 to help lower blood sugar levels. RinGlar binds to and activates the GLP-1 receptor, which stimulates insulin secretion and inhibits glucagon release.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients (NA)
- Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RinGlar® CI brief — competitive landscape report
- RinGlar® updates RSS · CI watch RSS
- Geropharm portfolio CI